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Library of dibenzazepine tethered 3,5-disubstituted isoxazolines were synthesised via 1,3-dipolar cycloaddition reaction and further an additional 
diversified group of dibenzazepine derivatives were accessed by Suzuki coupling of  6d  with various organoboronic acids. All these compounds 
were evaluated for their antimalarial activity against drug-sensitive Plasmodium falciparum 3D7 strain. Among the tested molecules, five 
compounds (6j, 6k, 8c, 8k and 8l) that highly inhibited the parasite growth were further assessed for antimalarial activity using an additional 
chloroquine-sensitive (D6) and two chloroquine-resistant (W2 and 7G8) P. falciparum strains. Molecular docking and dynamics simulation 
studies were performed to understand the binding mode and binding strengths of the selected compounds with the enzyme. 
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Malaria, a complex and deadly parasitic infectious disease, is a huge public health problem in many endemic countries 
around the globe. The prevailing extensive resistance of malaria parasites to traditional drugs and emergence of resistance 
to the currently used frontline artimisinin-based chemotherapy calls for the development of new drugs. Towards this 
objective and since compounds containing dibenzazepine moiety are effective in treating both gametocyte and asexual 
stage malaria parasites, including multi drug resistant parasites, a library of dibenzazepine tethered 3,5-disubstituted 
isoxazolines were synthesised via 1,3-dipolar cycloaddition reaction. An additional diversified group of dibenzazepine 
derivatives were accessed by Suzuki coupling of one the above dibenzazepine derivatives with various organoboronic 
acids. All compounds were structurally characterized and were evaluated for their antimalarial activity. They exhibited 
good to excellent inhibitory activity against the growth of drug-sensitive Plasmodium falciparum 3D7 strain with IC50 values 
ranging from 0.2 to 7.7 µM. About 50% of the compounds were either minimally or not toxic to human cell lines. Five of 
the compounds (6j, 6k, 8c, 8k and 8l) that highly inhibited the parasite growth were further assessed for antimalarial 
activity using an additional chloroquine-sensitive (D6) and two chloroquine-resistant (W2 and 7G8) P. falciparum strains. 
These compounds were effective against all four strains (3D7, D6, W2 and 7G8), exhibiting IC50 values of 0.1 to 1.75 µM. 
The dibenzazepines were identified to target metalloamino-peptidase of parasites. Molecular docking and dynamics 
simulation studies were performed to understand the binding mode and binding strengths of the selected compounds 
with the enzyme. In agreement with their excellent antimalarial activity, the data suggested that the compounds can 
strongly bind to the active site of the enzyme. 
 
Introduction  
Malaria is a deadly infectious disease in many tropical and 
subtropical countries of the world. Approximately 50% of the global 
population is at risk of contracting the disease. According to a 
recent WHO report, in 2013, ~200 million clinical cases of malaria 
were diagnosed, and ~600,000 deaths have occurred worldwide, 
most of which were in young children and in pregnant women.1 In 
addition to the huge death toll it exerts, malaria vastly curtails 
socioeconomic progress of people in the endemic areas, which are 
mostly underdeveloped, by causing frequent debilitating clinical 
conditions and thus, contributing to the loss of enormous 
productive manpower. Although five species of Plasmodium family 
of protozoan parasites can infect humans to cause malaria, P. 
falciparum and P. vivax are responsible for almost all malarial 
deaths. While P. falciparum is most prevalent in Africa, both P. vivax 
(majorly) and P. falciparum (to variable degrees) are prevalent in 
Southeast Asia including Indian subcontinent, some parts of Africa, 
and South America. Further, P. falciparum, the most virulent among 
malaria parasites that can infect human, accounts for >90% of all 
malarial deaths, whereas P. vivax is responsible for most of the 
remainder of deaths. 
Traditionally chloroquine and other quinine derivatives have been 
the most commonly used drugs to treat malaria. However, parasites 
have developed widespread resistance against these drugs.2 To 
overcome this problem, artemisinin-based combination therapy 
(ACT) has been developed as a frontline treatmnet.3,4 Although ACT 
has been effective in treating malaria and is still being widely used, 
resistance has emerged against this treatment in several Southeast 
Asian countries.5,6 Hence, development of new, effective 
antimalarial drugs is urgently needed. Towards this goal, our 
research group has recently reported the potential utility of 1,2-
disubstituted-4-quinolones and abietane diterpenoids as new 
antimalarial agents,7,8 and we have been continuing efforts to 
identify new classes of antimalarial agents. 
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The blood stage infection of Plasmodium parasites is responsible for 
the clinical symptoms and severe illnesses of malaria. The initial 
infection involves the entry of merozoites released from the 
matured liver stage parasites into erythrocytes, where they grow 
into trophozoites, which upon maturation undergo schizogony to 
form merozoites. At the end of 48 h intraerythrocytic life cycle of 
parasites, the merozoites released from infected erythrocytes 
invade new erythrocytes to start the next 48 h life cycle.9,10 During 
their growth in erythrocytes, parasites depends on the host 
products for nutritional need. For example, amino acids formed by 
the degradation of host cell haemoglobin by aminopeptidases are 
the main source for parasite protein synthesis.11,12 P. falciparum M1 
alanyl aminopeptidase (PfA-M1), a terminal zinc-metalloamino-
peptidase of hemoglobin digestion converts the cleaved 
hemoglobin peptides into an amino acid pool, which is used by 
parasites for its protein synthesis.13-15 Since hemoglobin-derived 
amino acids are critical for parasite growth, PfA-M1 is considered as 
a potential target for the development of antimalarial agents.16-19 
Compounds containing dibenzazepine 1 scaffold exhibit a wide 
range of biological activity and hence, a variety of derivatives have 
been synthesized and evaluated as antimicrobial and antifungal,20 
antioxidant,21,22 anticancer,23 antiepileptic,24 anticonvulasent,25-27 
and serotonin agents.28 Some examples of clinically important 
dibenzazepine-based drugs are carbamazepine,25,26,29 opipramol,30 
and oxacarbazepine24 that used for treating epilepsy, anxiety, and 
mood disorders. A recent report describes dibenzazepine 
derivatives as efficient antimalarial agents for both the gametocyte 
stage and the blood stage P. falciparum.31 The dibenzazepine 
moiety has also been used for the development of agents against 
multi drug resistant Plasmodium parasites.32 Given the potential 
usefulness of dibenzazepines as target-specific antimalarial agents 
and in view of exploring various new classes of compounds for 
antimalarial activity, we synthesized a library of dibenzazepines 
having substituted five-membered heterocyclic rings at the N-
position of the azepine ring and evaluated their antimalarial 
activity.  
Results and Discussion 
Chemistry 
At first, a series of 3,5-disubstituted isoxazolines (6a-6k) bearing 
aryl, heteroaryl and alicyclic group at the C-3 position of isoxazoline 
ring and having dibenzazepine moiety at the C-5 position were 
synthesized36 through the reactions depicted in Scheme 1. The 
synthon, dipolarophile 5-allyl-5H-dibenzazepine 2 was prepared by 
N-allylation of 5H-dibenzo[b,f]azepine 1 using allyl bromide in 
presence of tetra-n-butylammonium bromide (TBAB) as a phase 
transfer catalyst, sodium hydroxide as a base in the biphasic 
mixture of toluene-water in 1:1 ratio at 55 °C. The dipolar aryl nitrile 
oxides (5a-5k) was generated in-situ in two-step processes by the 
addition of hydroxylamine hydrochloride to aryl, heteroaryl or 
alicyclic aldehydes (3a-3k) in the presence of sodium acetate in 
methanol followed by the action of N-chlorosuccinimide (NCS) on 
oximes formed (4a-4k) in the presence of triethyl amine base 
(Scheme 1). Coupling of synthon 2 with aryl, heteroaryl or alicyclic 
nitrile oxides in the presence of triethyl amine afforded 
dibenzazepine tethered 3,5-disubstituted isoxazolines (6a-6k). The 
compounds were characterised by LC-MS, 1H and 13C NMR, and 
elemental analyses (see the supplementary file) 
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6a= p-(NO2)Ph  
6b= p-(F)Ph
6c= p-(Cl)Ph
6g= p-(OH)Ph
6h= p-(OCOPh)Ph
6i= p-(CF3)Ph
6d= p-(Br)Ph
6e= p, o-di-(Me)2Ph
6f= p-(OMe)Ph
6j= p-(3-pyridyl)Ph
6k= 4-piperidyl
Where, R1 =
Reagents and conditions: i) allyl bromide, TBAB, NaOH, toluene-water (1:1), 55 °C, 4h; ii) NH2OH.HCl, CH3COONa, CH3OH, RT, 3h; iii) NCS, 
Et3N, CHCl3, RT, 3h; iv) Et3N, CHCl3, 0 °C-RT, 6h.
Scheme 1  Synthesis of 3,5-disubstituted isoxazolines (6a-6k) from 5-allyl-5H-dibenzo[b,f]azepine 2. 
Dibenzazepine derivatives carrying substituents on the 
dibenzazepine ring were found to exhibit effective biological and 
pharmacological properties with minimal side effects.27,32 
Therefore, these class of compounds have been of special interest 
for exploiting as drug candidates. Considering this, an additional 
series of compounds (8a-8l) were prepared by introducing various 
substituents on the para-position of the C-3 phenyl moiety of 
isoxazoline ring in 6d. This was accomplished via Suzuki coupling of 
6d with various organoboronic acids (7a-7l) in the presence of 
Pd(dppf)Cl2.CH2Cl2 catalyst
37 using Cs2CO3 as base in dioxane-water 
biphasic solvent under nitrogen atmosphere (Scheme 2). The 
products were purified by column chromatography on silica gel (60-
120 mesh) using mixtures of ethyl acetate and hexane in suitable 
ratios and were characterised by LC-MS, 1H and 13C NMR, and 
elemental analyses (see the supplementary file). Additionally, 
compound 6d was characterized by single crystal XRD studies and 
the crystallographic data have been deposited at the CCDC No 
104958538 (Fig. S1, see the supplementary file). 
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8i= p-(CH2NHPh)Ph
8j= 2-thiophene
8k= 4-pyridyl 
8l= 5-(6-Chloro-1,3-dihydro-indol-2-one)
8a= p-(Cl)Ph
8b= p-(OH)Ph
8c= p-(OH)Ph 
8d= p-(CH2OH)Ph
8e= p-(CHO)Ph
8f= p-(OMe)Ph
8g= p-(OCF3)Ph
8h= p-(CN)Ph
70-90 %
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N
Br
N
O
N
R2
Where, R2 =
Reagents and conditions: i) Pd(dppf)Cl2.CH2Cl2, Cs2CO3, dioxane/water (6:1), 100 °C, 12 h.  
Scheme 2 Suzuki coupling of 5-[3-(4-bromo-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-dibenzo[b,f]azepine 6d with various boronic 
acids.  
 
Biology 
All the synthesized compounds (6a-6k and 8a-8l) were initially 
examined for antimalarial activity against chloroquine-sensitive P. 
falciparum 3D7 strain. The parasite growth inhibition was assessed 
at concentrations ranging from 0.1 to 100 µM by a SYBR Green 
assay.39,40 All compounds showed good to excellent antimalarial 
activity with IC50 values of 0.2 to 7.7 µM (Table 1). The cytotoxicity 
of the compounds was examined using human kidney embryonic 
(HEK 293) cells and human lung tumor epithelial cell (A549) by the 
MTS assay. Many of the compounds exhibited either minimal or no 
cytotoxicity (IC50 >40 µM), and others displayed low cytotoxicity (20 
to 40 µM) (Tables 1). The compounds, 6j, 6k, 8c, 8k, and 8l that 
showed inhibitory activity less than 2 µM were further assessed for 
their ability to inhibit an additional chloroquine-sensitive parasite 
(D6) strain and two chloroquine-resistant (W2 and 7G8) strains at 
concentrations ranging from 0.10 µM to 1.75 µM. Each of the five 
compounds inhibited both chloroquine-sensitive and chloroquine-
resistant parasites to similar extents (Table 2). Further, we tested 
6j, 6k, 8c, 8k and 8l for lysis of red blood cells at concentration 
ranging from 2.5 µM to 40 µM. The compounds were not lytic at or 
below 20 µM, suggesting that the antimalarial activity of 
dibenzazepines is not due to the lysis of red blood cells. 
 
 
 
 
 
 
 
Structure-activity relationship 
In efforts to understand the structure-activity relationship, first the 
activity of dibenzazepine 6-series derivatives having substituents at 
the para-position of the phenyl moiety at the C-3 position of 
isoxazoline ring was compared. Regardless of whether the 
substituents are electron-withdrawing groups such as -NO2 (6a), -F 
(6b), -Cl (6c), -Br (6d) and -CF3 (6i) or electron-releasing groups such 
as -CH3 (6f) and -OH (6g) groups, the compounds showed good to 
excellent parasite growth inhibitory activity. Interestingly, nitrogen-
containing hetero-alicyclic substituent piperidyl (6k) or hetero-
aromatic substituent pyridyl (6j) in place of phenyl moiety exhibited 
much higher inhibitory activity than the above compounds. 
However, compounds containing hydrophobic methyl substituents 
(6e) or ester substituent (6h) were relatively less active. This could 
be due to their expected lower solubility compared to other 
compounds. In 8a-8l series, in general, compounds having hydroxy- 
or methoxy-phenyl substituents (8b, 8c, 8d, and 8f) showed 
excellent inhibitory activity. As is the case of 6-series, compounds 
8k and 8l, bearing pyridyl or 2-indolone substituents, exhibited 
more potent activity. The remaining compounds, 8a, 8e, 8g, 8i, and 
8j, were relatively less active than others and there was no clear 
distinct structure-activity relationship was evident. 
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Table 1  Antimalarial activity of 3,5-disubstituted isoxazolines 
(6a-6k and 8a-8l) against drug-sensitive P. falciparum 3D7 strain 
and cytotoxicity against A549 and HEK 293 cells. 
a The fluorescence intensity was measured in a microliter plate reader. 
b The absorbance was measured in a microliter plate spectrophotometer. 
 
 
 
 
Target identification  
PASS Online structure-activity predictive program was used to 
identify the target molecule involved in blocking of malaria parasite 
growth by dibenzazepine derivatives.33,34 This program predicts 
many types of biological activity, including pharmacological effects, 
interaction with metabolic enzymes, transporters, and mechanisms 
of action by comparing the structures of test compounds with the 
data base. The prediction is based on statistical probability data 
that was developed based on the structure-activity relationships of 
a collection of structurally similar molecules. Searching for the 
probable targets suggested that PfA-M1 aminopeptidase is the 
most likely target candidate. Hence, binding mode of the 
dibenzazepine derivatives with PfA-M1 was analyzed by 
computational modeling studies. 
 
Table 2  Activity of selective dibenzazepine derivatives against 
drug-sensitive and drug-resistant P. falciparum. 
Parasite growth inhibition (IC50, µM ± SEM) 
Compound 3D7 D6 W2 7G8 
6j 0.58 ± 0.18 0.40  ± 0.08 0.36 ± 0.09 0.42 ± 0.06 
6k 0.19 ± 0.06 0.16 ± 0.04 0.12 ± 0.09 0.10 ± 0.06 
8c 1.75 ± 0.84 1.66 ± 0.16 1.22 ± 0.09 1.30 ± 0.12 
8k 0.99 ± 0.21 1.66 ± 0.04 1.10 ± 0.12 1.20 ± 0.02 
8l 1.15 ± 0.67 1.06 ± 0.13 0.92 ± 0.09 0.93 ± 0.15 
Chloroquine 0.13 ± 0.06 0.12 ± 0.08 0.32 ± 0.09 0.28 ± 0.03 
Mefloquine 0.04 ± 0.02 0.03 ± 0.06 0.16 ± 0.07 0.11 ± 0.03 
 
Molecular docking analysis 
The aim of the molecular docking study was to elucidate how 
dibenzazepine derivatives bind to the target PfA-M1, which cleaves 
hemoglobin-derived peptides. The docking results provided 
appropriate information about the binding affinity, binding energy 
and orientation of ligand-enzyme interactions to inhibit the 
function of PfA-M1. The molecular docking was carried out for all 
substituted dibenzazepine tethered 3,5-disubstituted isoxazoline 
derivatives with PfA-M1 and the interaction of ligands with protein 
was analyzed (Table S1, Supplementary file). The docking protocol 
was validated using the reported structure of PfA-M1 bound to its 
ligand. The root mean square (RMS) deviation between the actual 
and the predicted pose was 0.8 Å, which was well within the 
acceptable limit of 2.0 Å.39 
The compound 6d showed docking score of -6.68 kcal/mol. It 
exhibited combination of both electrostatic and hydrophobic 
interactions resulting in strong binding affinity. The oxygen and 
nitrogen atom of isoxazoline ring formed co-ordination bond with 
the Zn+2 ion with the bond length 2.2 Å and 2.5 Å, respectively; the 
dibenzazepine ring formed π−π parallel staking interactions with 
His496; the terminal aromatic ring formed π−π staking interactions 
with Tyr575; the bromine formed week halogen interactions with 
backbone carbonyl of Glu319; the residues Val493, Val523, Tyr580, 
Tyr575, Val459, Met462 formed hydrophobic interaction with 
ligand (Fig. 1, Table 3). 
The compound 6j exhibited docking score of -8.06 kcal/mol; the 
oxygen and nitrogen atom of isoxazoline ring of 6j formed co-
ordination bond with the Zn+2 ion with the bond length 2.3 Å and 
2.6 Å, respectively; the nitrogen atom of isoxazoline ring formed 
 Parasite growth inhibition IC50 (µM ± SD)  
 
Product         R1 3D7 Strain
 a
 A549 cells
 b
 HEK293 
cells
b
 
6a NO2
 
2.65 ± 0.95 >100 >100 
6b F
 
2.11 ± 0.74 18.40 ± 2.61 21.60 ± 1.51 
6c Cl
 
1.69 ± 0.28 18.60 ± 2.30 16.60 ± 3.14 
6d Br
 
1.42 ± 0.96 26.80 ± 4.51 31.60 ± 4.53 
6e 
CH3
H3C
 
3.35 ± 0.95 >100 >100 
6f O
CH3
 
2.27 ± 0.88 43.20 ± 3.66 40.16 ± 6.23 
6g OH
 
2.27 ± 0.88 24.10 ± 3.16 23.60 ± 4.36 
 
6h O
O
Ph
 
4.17 ± 1.20 42.10 ± 5.03 43.40 ± 5.20 
6i 
 
2.23 ± 0.85 23.40 ± 4.41 26.60 ± 3.22 
6j 
N
 
0.58 ± 0.18 28.40 ± 3.17 22.10 ± 3.22 
6k NH
 
0.19 ± 0.06 45.60 ± 5.62 44.80 ± 6.11 
8a Cl
 
7.70 ± 1.46 20.10 ± 3.94 36.40 ± 5.27 
8b OH
 
2.69 ± 1.49 36.70 ± 4.68 42.30 ± 5.09 
8c 
OH
 
1.75 ± 0.84 41.60 ± 3.13 31.90 ± 6.73 
8d 
OH
 
2.83 ± 1.06 33.60 ± 4.43 41.20 ± 3.50 
8e 
O
 
5.67 ± 1.63 21.20 ± 3.82 31.20 ± 3.61 
8f O
CH3
 
2.70 ± 0.94 56.20 ± 6.22 >100 
8g OCF3
 
4.79 ± 0.93 18.60 ± 4.20 29.10 ± 5.36 
8h N
 
2.63 ± 1.22 39.50 ± 4.63 44.30 ± 5.03 
8i 
HN
 
5.20 ± 1.10 46.40 ± 6.63 41.30 ± 5.15 
8j 
S
 
3.14 ± 0.93 42.40 ± 4.93 58.40 ± 4.66 
8k N
 
0.995 ± 0.21 >100 >100 
8l 
Cl N
H
O
 
1.15 ± 0.67 56.6 ± 6.72 50.10 ± 4.70 
CF3
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week H-bond with hydroxyl of Tyr580; the dibenzazepine ring 
formed π−π interactions with His496; the terminal pyridine ring 
formed edge to face type of π−π interactions with Tyr575; the 
residues Val493, V523, Tyr580, Tyr575, Val459, Met462, Met1034, 
Ala320 formed hydrophobic interaction with ligand (Table 3). 
The compound 6k exhibited potent in vitro antimalarial activity. The 
docking pose of 6k with protein showed strong combination of 
electrostatic and hydrophobic interactions with active site amino 
acid residues of PfA-M1, the observed docking score was -7.90 
kcal/mol. The oxygen and nitrogen atom of isoxazoline ring formed 
co-ordination bond with the Zn+2 ion with the bond length 2.3 Å and 
2.8 Å, respectively; the dibenzazepine ring formed π−π interactions 
with His496; the terminal piperidine ring formed strong ionic 
interaction (like salt bridge) with Glu572 and the protonated 
nitrogen of the piperidine ring formed π-cation interaction with 
Tyr575 resulting in high gain in binding affinity; the residues Val493, 
Tyr580, Tyr575, Val459, Met462, Met1034, Ala320 formed 
hydrophobic interaction with ligand (Fig. 1, Table 3). 
 
 
 
Fig. 1 Docking pose for compounds 6d, 6k, 8k and 8l with PfA-M1. The H-bonds are shown in pink colour dotted lines, π−π interactions 
are shown in blue colour dotted lines and π-cation interactions are shown in green colour dotted lines. 
To improve the mode of interaction and binding ability with the 
target, the structural modification on compound 6d was carried out 
and obtained several additional compounds (8 series) and tested for 
antimalarial activity. Of these, two compounds, 8k and 8l, that 
showed excellent activity were analysed for binding to PfA-M1. The 
docking score for compound 8k was -7.80 kcal/mol. The oxygen and 
nitrogen atom of isoxazoline ring formed co-ordination bond with 
the Zn+2 ion with the bond length 2.1 Å and 2.5 Å, respectively; the 
nitrogen atom of isoxazoline ring formed weak H-bond with 
hydroxyl group of Tyr580; the dibenzazepine ring formed π−π 
interactions with His496; the terminal pyridine ring and the 
penultimate phenyl ring formed edge to face π-π interaction with 
Tyr575; the residues V523, Val493, Tyr580, Tyr575, Val459, Met462, 
Met1034, Ala320 formed hydrophobic interaction with ligand (Fig. 
1, Table 3). 
The compound 8l showed a docking score of -7.30 kcal/mol. The 
oxygen and nitrogen atom of isoxazoline ring formed co-ordination 
bond with the Zn+2 ion with the bond length 2.2 Å and 2.3 Å 
respectively; the dibenzazepine ring formed π−π interactions with 
His496; the phenyl ring formed π−π staking interactions with 
Tyr575, the terminal carbonyl of 2-indolone formed H-bond with 
Asn458 and formed π−π staking interactions with Tyr575; the 
residues Val493, Val523, Tyr580, Tyr575, Val459, Met462, Met1034, 
Ala320 formed hydrophobic interaction with ligand (Fig. 1, Table 3). 
The ligand displayed combination of electrostatic and hydrophobic 
interactions, but the binding pose bumped on Van der Waals radii 
of the protein atoms, which could be the reason for observed 
decreased activity of 8l compared to 8k (Fig. 1, Table 3). 
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Table 3  Docking score and interaction residues for the binding of dibenzazepine derivatives with PfA-M1. 
 
Molecular dynamics simulation 
To confirm the stability of binding mode predicted by Glide docking 
of the compounds to PfA-M1 and to monitor the structural changes 
in the form of conformations and ligand-protein interactions, 
molecular dynamics (MD) simulation was performed. The docked 
complex of the most potent compound 6k was considered for the 
MD simulation. The complex was adequately soaked into simulation 
box consisted of 24,244 water molecules. The system was simulated 
for 50 ps for equilibration. The final simulation run was for a total of 
10 ns, during which 1000 structures enumerated were saved in the 
trajectory. To understand the stability of the complex during MD 
simulation, the protein backbone frames were aligned to the 
backbone of initial frame and then the RMS deviation was 
calculated with respect to the initial frame. The RMS deviations 
between the original structure and the structure enumerated 
during MD simulation were plotted (Fig. 2). The protein backbone 
RMS deviation recorded during simulation shows large deviation for 
the initial 500 ps due to the initial protein structural stabilization; 
after about 500 ps the system showed a steady state dynamics. The 
backbone structural deviations observed in protein for the latter 
phase of 2 to 10 ns was in the range of 1.28 Å to 1.69 Å compared 
to that of original structure. From 2 ns to till the end of simulation, 
the total RMS deviation of protein was within a range of 0.41 Å. This 
clearly suggests that 10 ns of simulation are sufficient for stabilizing 
this complex. To further confirm the structure stability of the 
protein, the RMS deviations between the side chain conformations 
of the amino acid residues was measured and found minimal RMS 
deviations of 0.43 Å after 2 ns (Fig. 2). 
 
Fig. 2 The RSM deviations between the original structure and the 
structure enumerated during MD simulation; the backbone 
fluctuations are shown in blue, ligand fluctuations are shown in 
green colour and the protein side chain fluctuations are shown in 
red colour. 
 
Further the RMS deviation of the ligand as shown in the Fig. 2, 
drastically reduced to 0.52 Å after 2 ns simulation. This strongly 
demonstrates that the ligand is well stabilized in binding site of the 
protein. Various inter-molecular interactions, including H-bond, 
hydrophobic, ionic, and electrostatic interactions were formed 
between ligand and protein during the MD simulation, making the 
ligand well stabilized in the binding pocket. The Fig. 3 shows the 
summary of the total interactions observed during the MD 
simulation. The stacked bar charts are normalized over the course 
of the trajectory. Values over 1.0 are possible as some amino acid 
residues could make multiple contacts of same subtype with the 
ligand. All the ligand-protein interactions found in the docking study 
were retained throughout the MD simulation. Fig. 4 shows a 
schematic diagram of the ligand interacting with the amino acid 
residues of protein structure evolved during MD simulation. 
Residues with the ligand interactions that occurred more than 25% 
of the simulation time in the trajectory are shown. The total 
number of specific contacts the protein made with the ligand over 
the course of the trajectory is shown in Fig. 5. From the structure 
evolved from the MD simulation, it is evident that ionic interaction 
Compound 
Docking score  
(kcal/mol) 
Metal 
coordinate bond   
π−π stacking  or π−cat
ion interaction  
H-bond forming 
residues 
Hydrophobic interaction residues 
6d -6.68 With  Zn+2 His496,  Tyr575     - Val493, Val523, Tyr580, Tyr575, 
Val459, Met462 
6j -8.06 With  Zn+2 His496,  Tyr575 Tyr580 Val493, V523, Tyr580, Tyr575, Val459, 
Met462, Met1034, Ala320 
6k -7.90 With  Zn+2 His496, Tyr575 Glu572 Val493, Tyr580, Tyr575, Val459, 
Met462, Met1034, Ala320 
8k -7.80 With  Zn+2 His496, Tyr575 Tyr580 Val493, Tyr580, Tyr575, Val459, 
Met462, Met1034, Ala320 
8l -7.30 With  Zn+2 His496, Tyr575 Asn458 Val493, Val523, Tyr580, Tyr575, 
Val459, Met462, Met1034, Ala320 
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with Glu572, co-ordination bond formation with Zn+2, the π-cation 
interaction with Tyr575 and hydrophobic interaction with Tyr580 of 
ligand is contributing strongly for the binding affinity; the π-cation 
interaction with Arg489 and π−π interactions with His496 were also 
observed. The water mediated bridged interaction between the 
amino acid residues Glu319 and Glu463 further stabilizing the 
ligand in the pocket. 
 
 
Fig. 3 Interaction between PfA-M1 and 6k evolved during MD 
simulation. 
 
 
 
Fig. 4 Schematic diagram of ligand interaction with the amino acid 
residues of protein evolved during MD simulation. Interactions that 
occur more than 25% of the simulation time are shown. 
 
 
Fig. 5 A timeline representation of the interactions and contacts 
(H-bonds, and hydrophobic and ionic interactions, and water 
bridges). The top panel shows the total number of specific contacts 
the protein makes with ligand over the course of trajectory. The 
bottom panel shows the residues that interact with the ligand in 
each trajectory frame. The residues making more than one contact 
are shown in darker colour shade. 
 
Experimental Section 
Materials and methods: The starting chemicals used here were 
purchased from commercial sources. The solvents were of 
analytical grade and were used without further purification. 
Reactions were monitored by thin-layer chromatography (TLC) 
using pre-coated sheets of silica gel 60 (Merck 60F254, 0.25 mm 
thickness) and visualization under UV light. The specific molecule 
purified by preparative HPLC, waters SPD-4245, USA. The melting 
points were determined on SELACO melting point apparatus and 
are uncorrected. 1H NMR (400 MHz) and 13C NMR (100 MHz) 
spectra were obtained using Agilent and Bruker NMR spectrometer, 
respectively. Chemical shifts (δ) are given in parts per million (ppm) 
using the residue solvent (CDCl3 and DMSO-d6) peaks as reference 
relative to TMS. Coupling constant (J) values are given in Hz. 
Electrospray ionization (ESI) mass spectral analysis was performed 
using Waters-Synapt G2 mass spectrometer. The C, H, and N 
analysis were performed using CE-400 CHN analyser. Infrared 
spectra were recorded on Shimadzu FT-IR model 8300 
spectrophotometer. 
 
Experimental procedure for the synthesis of 5-allyl-5H-
dibenzo[b,f]azepine (2)   
To 5H-dibenzazepine (1, 25.8 mmol) in a mixture of toluene and 
water in the ratio of 1:1 was added sodium hydroxide (51.7 mmol) 
followed by TBAB (2.5 mmol) at room temperature. After 15 
minutes, allyl bromide was added drop wise (38.8 mmol) at room 
temperature. The reaction mixture was heated at 55 °C for 4 h. 
After completion of the reaction as monitored by TLC, the reaction 
mixture was diluted with water (100 mL) and the aqueous layer was 
extracted with ethyl acetate (3 x 50 mL). The combined ethyl 
acetate layer was washed with 0.1 N hydrochloric acid (2 x 50 mL), 
followed by brine solution (2 x 50 mL). The organic layer was dried 
over anhydrous sodium sulphate, filtered, and concentrated under 
reduced pressure. The crude compound 2, was purified by column 
chromatography over silica gel (60-120 mesh) using hexane:ethyl 
acetate mixture in 9.5:0.5 ratios as eluent. The crude compound, 
allyl-5H-dibenzo[b,f]azepine (2), was crystallized in ethyl acetate 
and hexane mixture to obtain yellow crystals. 
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5-Allyl-5H-dibenzo[b,f]azepine (2) 
Yield 95%; yellow crystal; mp 40-42 °C; FT-IR (cm-1): 3015, 1623, 
1515, 1475, 1262; 1H NMR (400 MHz, CDCl3): δ 4.40 (d, J = 5.6 Hz, 
2H,  -C=CH2), 5.10 (dd, J1-2 = 10.4 Hz, J1-3 = 1.2 Hz, 1H, N-CH), 5.30 
(dd, J1-2 = 17.2 Hz, J1-3 = 1.2 Hz, 1H, N-CH), 5.74-5.84 (m, 1H, -C=C-H), 
6.75 (s, 2H, ArH), 6.98 (t, J = 6.26 Hz, 4H, ArH), 7.06 (dd, J1-2 = 8 Hz, 
J1-3 = 1.6 Hz, 2H, ArH), 7.24 (td, J1-2 = 8 Hz, J1-3 = 1.2 Hz, 2H, ArH); 
13C 
NMR (100 MHz, CDCl3): δ 53.54, 117.5, 120.5, 123.3, 128.6, 129.1, 
132.2, 133.7, 135.1, 150.7; MS (ESI): m/z = 234.1 [M+H]+; elemental 
composition calculated for C17H15N: C, 87.52; H, 6.48; N, 6.00; 
Found: C, 87.56; H, 6.55; N, 6.04. 
 
General procedure for the synthesis of isoxazolines 
Preparation of aldoxime (4a-4k) 
To a solution of aldehyde (7.1 mmol) in methanol was added 
hydroxyl amine hydrochloride (7.8 mmol) followed by sodium 
acetate (7.8 mmol). The mixture was stirred at room temperature. 
After completion of the reaction as monitored by TLC, the reaction 
was quenched by adding crushed ice and the white precipitate 
formed was isolated by filtration, washed with hexane, and dried.  
Synthesis of isoxazoline derivatives (6a-6k) 
For chlorination of aldoximes (4a-4k), their solutions of aldoximes 
(4.1 mmol) in chloroform at room temperature was added NCS (4.5 
mmol) and stirring was continued for 3 h, reaction progress was 
monitored by TLC. The reaction mixture was cooled to 0 °C and 
slowly added triethyl amine (10.25 mmol). After 10 minutes, the 
solution of 5-allyl-5H-dibenzazepine 2 in DMF (4.1 mmol) was 
added dropwise at 0 °C. The stirring was continued for 6-8 h at 0 °C 
to room temperature. The reaction mixture was diluted with 
chloroform (2 x 25 mL), the combined organic layer was washed 
with 0.1 N hydrochloric acid (2 x 20 mL), followed by brine solution 
(2 x 20 mL). Then, the organic layer was dried over anhydrous 
sodium sulphate, filtered and concentrated under reduced 
pressure. The crude products (6a-6k), were purified by column 
chromatography over silica gel (60-120 mesh) using hexane:ethyl 
acetate mixture in 8:2 ratios as eluent. The compounds (6a-6k) 
were crystallized in ethyl acetate and hexane mixture. 
 
5-[3-(4-Nitro-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6a) 
Yield 72%; yellow crystal; mp 166-168 °C; FT-IR (cm-1): 2993, 1727, 
1519, 1484, 1269, 1169, 909, 764, 704; 1H NMR (400 MHz, CDCl3): δ 
3.21 (dd, J1-2 = 16.8 Hz, J1-1 = 10.8 Hz, 1H, C4-H isoxazoline), 3.46 (dd, 
J1-2 = 17.2 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 3.58 (dd, J1-2 = 12.8 Hz, J1-1 = 
8.8 Hz, 1H, C4-H isoxazoline), 4.32 (dd, J1-2 = 13.2 Hz, J1-1 = 4.4 Hz, 
1H, N-CH), 4.94 -5.02 (m, 1H, C5-H isoxazoline), 6.70 (q, J = 11.6 Hz, 
2H, ArH), 6.98-7.04 (m, 4H, ArH), 7.09 (d, J = 6.4 Hz, 1H, ArH), 7.18 
(d, J = 8.0 Hz, 1H, ArH),  7.23-7.31 (m, 2H, ArH), 7.73 (d, J = 8.8 Hz, 
2H, ArH),  8.20 (d, J = 8.8 Hz, 2H, ArH); 13C NMR (100 MHz, CDCl3): δ 
37.7, 53.5, 79.7, 120.7, 120.9, 123.8, 124.0, 124.1, 127.3, 129.0, 
129.2, 129.4, 131.8, 132.1, 133.5, 134.2, 135.7, 148.3, 148.4, 151.1, 
154.9; MS: m/z = 397.4 (calculated), m/z = 398.8 [M+H]+ (found); 
elemental composition calculated for C24H19N3O3: C, 72.53; H, 4.82; 
N, 10.57; O, 12.08; found: C, 72.56; H, 4.89; N, 10.59. 
5-[3-(4-Fluoro-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6b) 
Yield 76%; yellow solid; mp 98-100 °C; FT-IR (cm-1): 2980, 1731, 
1523, 1489, 1260, 1153, 901, 764; 1H NMR (400 MHz, CDCl3): δ 3.19 
(dd, J1-2 = 16.8 Hz, J1-1 = 10.4 Hz, 1H, N-CH), 3.83-3.52 (m, 2H, C4-2H 
isoxazoline), 4.35 (dd, J1-2 = 12.8 Hz, J1-1 = 4.0 Hz, 1H, N-CH), 4.87-
4.94 (m, 1H, C5-H isoxazoline), 6.73 (d, J = 2.4 Hz, 2H, ArH), 7.10-
6.98 (m, 7H, ArH), 7.18-7.23 (m, 2H, ArH), 7.27-7.32 (m, 1H, ArH), 
7.56-7.60 (m, 2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.3, 54.2, 
78.7, 115.9, 116.3, 121.3, 121.4, 124.0, 126.4, 126.5, 129.1, 129.2, 
129.4, 129.5, 132.3, 132.5, 133.9, 150.4, 150.7, 155.9, 162.1, 164.6; 
MS: m/z = 370.4 (calculated), m/z = 371.5 [M+H]+ (found); 
elemental composition calculated for: C24H19FN2O: C, 77.82; H, 5.17; 
F, 5.13; N, 7.56; O, 4.32; found: C, 77.84; H, 5.21; N, 7.58. 
5-[3-(4-Chloro-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine  (6c) 
Yield 82%; Yellow solid; mp 155-157 °C; FT-IR (cm-1): 2925, 1593, 
1494, 1485, 1456, 1434, 1355, 1238, 1179; 1H NMR (400 MHz, 
CDCl3): δ 3.18 (dd, J1-2 = 16.8 Hz, J1-1 = 10.4 Hz, 1H, C4-H isoxazoline), 
3.40 (dd, J1-2 = 16.8 Hz, J1-1 = 6.0 Hz, 1H, C4-H isoxazoline), 3.51 (dd, 
J1-2 = 12.8 Hz, J1-1 = 9.2 Hz, 1H, N-CH), 4.33 (dd, J1-2 = 12.8 Hz, J1-1 = 
4.4 Hz, 1H, N-CH), 4.87-4.95 (m, 1H, C5-H isoxazoline), 6.73 (q, J = 
11.2 Hz, 2H, ArH), 6.98- 7.05 (m, 4H, ArH), 7.09 (d, J = 7.6 Hz, 1H, 
ArH), 7.18-7.23 (m, 2H, ArH), 7.27-7.33 (m, 3H, ArH), 7.51-7.54 (m, 
2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.1, 54.2, 79.0, 121.3, 
124.1, 128.6, 128.8, 129.2, 129.5, 132.2, 132.5, 133.9, 134.9, 156.0; 
MS: m/z = 386.8 (calculated), m/z = 387.5 [M+H]+ (found); 
elemental composition calculated for: C24H19ClN2O: C, 74.51; H, 
4.95; Cl, 9.16; N, 7.24; O, 4.14; found: C, 74.53; H, 4.99; N, 7.25. 
5-[3-(4-Bromo-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6d) 
Yield 83%; brown solid; mp 138-140 °C; FT-IR (cm-1): 2923, 1590, 
1486, 1457, 1398, 1347, 1235, 1158, 1114; 1H NMR (400 MHz, 
CDCl3): δ 3.17 (dd, J1-2 = 17.2 Hz, J1-1 = 10.8 Hz, 1H, C4-H isoxazoline), 
3.39 (dd, J1-2 = 16.8 Hz, J1-1 = 6.0 Hz, 1H, N-CH), 3.50 (dd, J1-2 = 12.8 
Hz, J1-1 = 9.2 Hz, 1H, C4-H isoxazoline), 4.31 (dd, J1-2 = 12.8 Hz, J1-1 = 
4.4 Hz, 1H, N-CH), 4.89-4.91 (m, 1H, C5-H isoxazoline), 6.72 (d, J = 
3.2 Hz, 2H, ArH), 7.04 (q, J = 15.6 Hz, 3H, ArH), 7.09 (d, J = 6.4 Hz, 
1H, ArH), 7.18 (d, J = 8.0 Hz, 1H, ArH), 7.22-7.30 (m, 3H, ArH), 7.43-
7.49 (m, 4H, ArH); 13C NMR (100 MHz, CDCl3): δ 38.2, 53.6, 78.8, 
120.7, 120.9, 123.9, 124.0, 124.2, 128.1, 128.5, 129.0, 129.1, 129.2, 
129.4, 131.7, 131.8, 132.2, 133.5, 134.2, 148.4, 151.4, 155.6; MS: 
m/z = 431.3 (calculated), m/z = 431.9 [M+H]+ (found); elemental 
composition calculated for: C24H19BrN2O: C, 66.83; H, 4.44; Br, 
18.53; N, 6.49; O, 3.71; found: C, 66.86; H, 4.49; N, 6.71. 
5-[3-(2,4-Dimethyl-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6e) 
Yield 78%; yellow gummy solid; FT-IR (cm-1): 2935, 1590, 1484, 
1481, 1453, 1424, 1359, 1231, 1199; 1H NMR (400 MHz, CDCl3): δ 
2.23 (S, 3H, CH3), 2.37 (S, 3H, CH3), 3.18 (dd, J1-2 = 16.8 Hz, J1-1 = 10.4 
Hz, 1H, C4-H isoxazoline), 3.36-3.42 (m, 2H, N-CH and C4-H 
isoxazoline), 4.25 (dd, J1-2 = 12.8 Hz, J1-1 = 4.4 Hz, 1H, N-CH), 4.75 (t, 
J = 4.8 Hz, 1H, C5-H isoxazoline), 6.65 (S, 2H, ArH), 6.90 -7.02 (m, 7H, 
ArH), 7.08-7.22 (m, 4H, ArH); 13C NMR (100 MHz, CDCl3): δ 21.1, 
22.9, 41.1, 53.5, 77.0, 120.7, 120.9, 123.8, 124.0, 125.7, 126.3, 
128.9, 129.02, 129.09, 129.1, 129.4, 131.9, 132.1, 132.3, 133.5, 
134.2, 137.8, 139.2, 148.5, 151.7, 157.3; MS: m/z = 380.48 
(calculated), m/z = 381.3 [M+H]+ (found); elemental composition 
calculated for C26H24N2O: C, 82.07; H, 6.36; N, 7.36; O, 4.21; Found: 
C, 82.09; H, 6.40; N, 4.23. 
5-[3-(4-Methoxy-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6f)  
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Yield 75%; orange gummy solid; FT-IR (cm-1): 2953, 1575, 1491, 
1466, 1376, 1339, 1237, 1160, 1101; 1H NMR (400 MHz, CDCl3): δ 
3.26 (dd, J1-2 = 16.4 Hz, J1-1 = 10.0 Hz, 1H, C4-H isoxazoline), 3.44-
3.49 (m, 2H, C4-H isoxazoline and N-CH), 3.81 (s, 3H, OCH3), 4.33 
(dd, J1-2 = 12.8 Hz, J1-1 = 4.4 Hz, 1H, N-CH), 6.73 (s, 2H, ArH), 4.80-
4.85 (m, 1H, C5-H isoxazoline), 6.97-7.03 (m, 7H, ArH), 7.09 (dd, J1-2 
= 7.6 Hz, J1-3 = 1.6 Hz, 1H, ArH), 7.15-7.23 (m, 3H, ArH), 7.26-7.32 
(m, 1H, ArH); 13C NMR (100 MHz, CDCl3): δ 38.3, 55.5, 55.6, 79.7, 
114.5, 120.3, 120.6, 120.7, 122.0, 123.7, 129.0, 129.1, 130.5, 132.1, 
133.5, 146.5, 150.1, 159.6; MS: m/z = 382.4 (calculated), m/z = 
383.3 [M+H]+ (found); elemental composition calculated for: 
C25H22N2O2: C, 78.51; H, 5.80; N, 7.32; O, 8.37; found: C, 78.54; H, 
5.88; N, 7.35. 
4-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
phenol (6g) 
Yield 70%; buff white solid; mp 169-171 °C; FT-IR (cm-1): 3210, 2924, 
1598, 1521, 1485, 1459, 1437, 1360, 1276, 1188, 1128; 1H NMR 
(400 MHz, CDCl3): δ 3.23 (dd, J1-2 = 16.8 Hz, J1-1 = 10.8 Hz, 1H, C4-H 
isoxazoline), 3.42-3.54 (m, 2H, C4-H isoxazoline and N-CH), 4.35 (dd, 
J1-2 = 12.8 Hz, J1-1 = 4.4 Hz, 1H, N-CH), 4.89-4.96 (m, 1H, C5-H 
isoxazoline), 6.74 (d, J = 1.2 Hz, 2H, ArH), 6.99-7.06 (m, 4H, ArH), 
7.10 (dd, J1-2 = 7.6 Hz, J1-3 = 1.6 Hz, 1H, ArH), 7.19-7.25 (m, 4H, ArH), 
7.28-7.33 (m, 1H, ArH), 7.49-7.53 (m, 2H, ArH), 9.20 (s, 1H, ArH); 13C 
NMR (100 MHz, CDCl3): δ 38.2, 54.5, 77.2, 120.2, 120.3, 121.5, 
123.8, 129.1, 129.2, 129.7, 132.1, 133.5, 134.2, 135.5, 147.0, 149.9; 
MS: m/z = 368.43 (calculated), m/z = 369.0 [M+H]+ (found); 
elemental composition calculated for: C24H20N2O2: C, 78.24; H, 5.47; 
N, 7.60; O, 8.69; found: C, 78.25; H, 5.49; N, 7.61. 
Benzoic acid 4-(5-dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-
isoxazol-3-yl)-phenyl ester (6h) 
Yield 80%; yellow solid; mp 140-142 °C; FT-IR (cm-1): 2990, 1727, 
1484, 1269, 1169, 909, 764, 704; 1H NMR (400 MHz, CDCl3): δ 3.30-
3.43 (m, 2H, C4-2H isoxazoline), 3.82 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 
1H, N-CH), 4.05 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.75-4.80 
(m, 1H, C5-H isoxazoline), 6.77 (d, J = 1.6 Hz, 2H, ArH), 7.03 (d, J = 
5.6 Hz, 2H, ArH),  7.10-7.23 (m, 4H, ArH), 7.30-7.37 (m, 4H, ArH), 
7.59-7.69 (m, 4H, ArH), 7.76 (t, J = 7.2 Hz, 1H, ArH), 8.14 (d, J = 7.2 
Hz, 2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.3, 54.2, 78.8, 
121.3, 121.4, 122.8, 124.1, 127.7, 128.2, 129.1, 129.4, 129.5, 130.3, 
132.3, 132.5, 133.9, 134.6, 150.4, 150.7, 152.1, 156.1, 164; MS: m/z 
= 472.5 (calculated), m/z = 473.6 [M+H]+ (found); elemental 
composition calculated for: C31H24N2O3: C, 78.79; H, 5.12; N, 5.93; 
O, 10.16; found: C, 78.80; H, 5.17; N, 5.95. 
5-[3-(4-Trifluoromethyl-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-
5H-dibenzo[b,f]azepine azepine (6i) 
Yield 83%; yellow solid; mp 143-145 °C; FT-IR (cm-1): 2940, 1593, 
1485, 1457, 1457, 1410, 1323, 1229, 1163, 1127; 1H NMR (400 MHz, 
CDCl3): δ 3.21 (dd, J1-2 = 17.2 Hz, J1-1 = 10.8 Hz, 1H, N-CH), 3.42-3.57 
(m, 2H, C4-2H isoxazoline), 4.33 (dd, J1-2 = 12.8 Hz, J1-1 = 4.4 Hz, 1H, 
N-CH), 4.92-4.99 (m, 1H, C5-H isoxazoline), 6.72 (q, J = 11.2 Hz, 2H, 
ArH), 6.90-7.05 (m, 4H, ArH), 7.10 (d, J = 6.4 Hz, 1H, ArH), 7.19 (d, J 
= 8.0 Hz, 1H, ArH), 7.23-7.32 (m, 2H, ArH), 7.61 (d, J = 8.4 Hz, 2H, 
ArH), 7.70 (d, J = 8.4 Hz, 2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 
37.9, 54.1, 79.4, 121.3, 121.4, 123.1, 124.1, 125.8, 126.03, 126.07, 
126.1, 127.6, 129.3, 129.5, 130.0, 130.3, 130.6, 132.2, 132.5, 133.8, 
133.9, 150.4, 150.6, 156.0; MS: m/z = 420.4 (calculated), m/z = 
421.5 [M+H]+ (found); elemental composition calculated for: 
C25H19F3N2O: C, 71.42; H, 4.56; F, 13.56; N, 6.66; O, 3.81; found: C, 
71.45; H, 4.59; N, 6.67. 
5-[3-(4-Pyridin-3-yl-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (6j) 
Yield 76%; pale brown solid; mp 162-164 °C; FT-IR (cm-1): 2922, 
2853,1732, 1583, 1583, 1571, 1484, 1433, 1407, 1358, 1334, 1298, 
1240, 1225, 1162; 1H NMR (400 MHz, CDCl3): δ 3.26 (dd, J1-2 = 16.8 
Hz, J1-1 = 10.4 Hz, 1H, N-CH), 3.45-3.57 (m, 2H, C4-2H isoxazoline), 
4.35 (dd, J1-2 = 12.8 Hz, J1-1 = 4.4 Hz, 1H, N-CH), 4.90-4.97 (m, 1H, C5-
H isoxazoline), 6.73 (d, J = 2.8 Hz, 2H, ArH), 6.98-7.05 (m, 4H, ArH), 
7.10 (d, J = 7.6 Hz, 1H, ArH), 7.22 (t, J = 8.4 Hz, 2H, ArH),  7.30 (t, J = 
7.2 Hz, 1H, ArH), 7. 02-7.84 (m, 5H, ArH), 8.00 (d, J = 8.4 Hz, 2H, 
ArH), 8.34 (d, J = 4.4 Hz, 1H, ArH); 13C NMR (100 MHz, CDCl3): δ 
38.1, 54.2, 78.2, 120.2, 120.3, 120.4, 123.8, 124.0, 127.8, 129.1, 
129.2, 132.1, 133.5, 133.6, 141.4, 147.4, 149.6, 149.9; MS: m/z = 
429.5 (calculated), m/z = 430.0 [M+H]+ (found); elemental 
composition calculated for: C29H23N3O: C, 81.09; H, 5.40; N, 9.78; O, 
3.73; found: C, 81.10; H, 5.46; N, 9.79. 
5-(3-Piperazin-1-yl-4,5-dihydro-isoxazol-5-ylmethyl)-5H-
dibenzo[b,f]azepine (6k) 
Yield 67%; buff white solid; mp 126-128 °C; FT-IR (cm-1): 3400, 2712, 
1593, 1483, 1458, 1308, 1224, 1160; 1H NMR (400 MHz, CDCl3): δ 
1.85-2.01 (m, 4H, 2CH2 piperidine), 2.5-2.52 (m, 1H, CH piperidine), 
2.78 (dd, J1-2 = 17.2 Hz, J1-1 = 10.8 Hz, 1H, C4-H isoxazoline), 2.90-
3.01 (m, 3H, CH2 piperidine and N-CH), 3.32 (S, 2H, CH2 piperidine), 
3.41 (dd, J1-2 = 12.8 Hz, J1-1 = 9.2 Hz, 1H, C4-H isoxazoline), 4.22 (dd, 
J1-2 = 12.8 Hz, J1-1 = 4.0 Hz, 1H, N-CH), 4.67-4.73 (m, 1H, C5-H 
isoxazoline), 5.18 (br, 1H, NH), 6.72 (d, J = 2.0 Hz, 2H, ArH), 7.04 (t, J 
= 6.4 Hz, 3H, ArH), 7.05-7.07 (m, 2H, ArH), 7.12 (d, J = 8.4 Hz, 1H, 
ArH), 7.23-7.28 (m, 2H, ArH); 13C NMR (100 MHz, CDCl3): δ 26.0, 
29.6, 33.1, 38.8, 43.0, 53.4, 77.6, 120.7, 121.0, 123.9, 124.0, 129.0, 
129.1, 129.2, 129.4, 131.9, 132.1, 133.5, 134.2, 148.5, 151.3, 159.2; 
MS: m/z = 359.464 (calculated), m/z = 360.189 [M+H]+ (found); 
elemental composition calculated for C23H25N3O: C, 76.85; H, 7.01; 
N, 11.69; O, 4.45; found: C, 76.88; H, 7.05; N, 11.70; O, 4.49. 
 
Experimental procedure for Suzuki coupling reaction 
5-[3-(4-Bromo-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine 6d  (1.1 mmol) and aryl boronic acid (7a-7l),  
(1.1 mmol) were dissolved in a mixture of 1,4-dioxane (6 mL), H2O 
(1mL) in a seal tube under nitrogen atmosphere. To the solution 
was added Pd(dppf)Cl2.DCM (0.1 mmol) followed by Cs2CO3 
(3.3mmol). The resulting mixture was heated under reflux at 100 °C 
for 12h. The reaction was monitored by TLC and the solution was 
filtered on celite. To the clear filtrate was added ethyl acetate (3 x 
25 mL), washed sequentially with water (2 x 25 mL) and brine (2 x 
25 mL), dried over anhydrous Na2SO4, filtered and distilled under 
reduced pressure. The crude products (8a-8l) were purified by 
column chromatography on silica gel (60-120 mesh) using 
hexane:ethyl acetate mixture in 7:3 ratios as eluent. 
5-[3-(4'-Chloro-biphenyl-4-yl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (8a) 
Yield 82%; yellow solid; mp 165–167 °C; FT-IR (cm-1): 2986, 2873, 
1762, 1576, 1573, 1561, 1474, 1433, 1360, 1278, 1230, 1152; 1H 
NMR (400 MHz, DMSO-d6): δ 3.25 (dd, J1-2 = 17.2 Hz, J1-1 = 6.8 Hz, 
1H, C4-H isoxazoline), 3.37 (dd, J1-2 = 17.2 Hz, J1-1 = 10.8 Hz, 1H, C4-H 
isoxazoline), 3.75 (dd, J1-2 = 14.0 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.01 
(dd, J1-2 = 19.6 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.69-4.74 (m, 1H, C5-H 
isoxazoline),  6.72 (d, J = 2.4 Hz,  2H, ArH), 6.97-7.27 (m, 8H, ArH), 
7.41(d, J = 8.4 Hz, 2H, ArH), 7.61 (d, J = 8.0 Hz, 2H, ArH), 7.66-7.69 
(m, 4H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.2, 54.2, 78.7, 
121.4, 124.0, 127.3, 127.5, 128.8, 129.2, 129.4, 129.5, 129.5, 132.2, 
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133.2, 133.9, 138.4, 140.4, 150.3, 150.7, 156.4; MS: m/z = 462.97 
(calculated), m/z = 463.4 [M+H]+ (found); elemental composition 
calculated for C30H23ClN2O: C, 77.83; H, 5.01; Cl, 7.66; N, 6.05; O, 
3.46; found: C, 77.85; H, 5.08; N, 6.06; O, 3.47. 
4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-4-ol (8b) 
Yield 79%; yellow solid; mp 119–121 °C; FT-IR (cm-1): 2985, 1585, 
1482, 1306, 1200, 1047; 1H NMR (400 MHz, DMSO-d6): δ 3.25 (dd, 
J1-2 = 16.0 Hz, J1-1 = 5.6 Hz, 1H, C4-H isoxazoline), 3.40 (d, J = 3.2 Hz, 
1H, C4-H isoxazoline), 3.75 (dd, J1-2 = 12.8 Hz, J1-1 = 5.6 Hz, 1H, N-
CH), 4.02 (dd, J1-2 = 13.6 Hz, J1-1 = 5.2 Hz, 1H, N-CH), 4.72-4.74 (m, 
1H, C5-H isoxazoline), 6.75 (s, 2H, ArH), 6.85 (d, J = 7.6 Hz, 2H, ArH), 
7.00-7.36 (m, 8H, ArH), 7.51 (d, J = 7.6 Hz, 2H, ArH), 7.60 (d, J = 8.1 
Hz, 4H, ArH), 9.63 (s, 1H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 
38.3, 54.2, 78.5, 116.0, 116.2, 121.3, 124.0, 126.4, 127.4, 127.7, 
128.2, 129.4, 129.5, 130.2, 132.2, 132.4, 133.8, 141.9, 156.5, 158.0; 
MS: m/z = 444.52 (calculated), m/z = 445.1 [M+H]+ (found); 
elemental composition calculated for C30H24N2O2: C, 81.06; H, 5.44; 
N, 6.30; O, 7.20; found: C, 81.09; H, 5.50; N, 6.32; O, 7.21. 
4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-3-ol (8c) 
Yield 89%; pale brown solid; mp 108-110 °C; FT-IR (cm-1): 3419, 
2988, 2254, 1659, 1481, 1244, 1050, 1023; 1H NMR (400 MHz, 
DMSO-d6): δ 3.23 (dd, J1-2 = 17.2 Hz, J1-1 = 6.4 Hz, 1H, C4-H 
isoxazoline), 3.36 (dd, J1-2 = 16.8 Hz, J1-1 = 10.4 Hz, 1H, C4-H 
isoxazoline), 3.73 (dd, J1-2 = 11.2 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.00 
(dd, J1-2 = 13.2 Hz, J1-1 = 6.0 Hz, 1H, N-CH), 4.68-4.72 (m, 1H, C5-H 
isoxazoline), 6.73 (d, J = 1.6 Hz,  2H, ArH), 6.80-6.83 (m, 2H, ArH), 
6.98-7.27 (m, 8H, ArH), 7.47-7.50 (m, 12H, ArH), 7.54-7.61 (m, 6H, 
ArH), 9.32 (s, 1H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.3, 54.2, 
78.5, 115.9, 116.2, 121.3, 124.0, 126.4, 127.4, 127.7, 128.1, 129.5, 
130.3, 131.6, 132.2, 133.9, 141.9, 150.3, 150.7, 156.5, 156.6, 158.0; 
MS: m/z = 444.52 (calculated), m/z = 445.1 [M+H]+ (found); 
elemental composition calculated for C30H24N2O2: C, 81.06; H, 5.44; 
N, 6.30; O, 7.20; found: C, 81.09; H, 5.50; N, 6.32; O, 7.21. 
 [4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-4-yl]-methanol (8d) 
Yield 90%; yellow solid; mp 145-147 °C; FT-IR (cm-1): 3445, 2250, 
2135, 1672, 1055, 1001; 1H NMR (400 MHz, DMSO-d6): δ 3.28 (dd, 
J1-2 = 16.8 Hz, J1-1 = 6.4 Hz, 1H, C4-H isoxazoline), 3.40 (dd, J1-2 = 16.8 
Hz, J1-1 = 10.8 Hz, 1H, C4-H isoxazoline), 3.75 (dd, J1-2 = 13.6 Hz, J1-1 = 
6.4Hz, 1H, N-CH), 4.01 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 
4.54 (d, J = 5.6 Hz, 2H, OCH2), 4.70-4.74 (m, 1H, C5-H isoxazoline), 
5.22 (t, J = 11.6 Hz, 1H, ArH), 6.73 (d, J = 2.4 Hz, 2H, ArH), 6.98-7.31 
(m, 9H, ArH), 7.39 (t, J = 8.4 Hz, 1H, ArH), 7.51 (d, J = 7.6 Hz, 1H, 
ArH), 7.62 (d, J = 8.4 Hz, 3H, ArH), 7.68 (d, J = 8.8 Hz, 2H, ArH); 13C 
NMR (100 MHz, DMSO-d6): δ 38.2, 54.2, 63.2, 78.6, 121.3, 124.0, 
125.0, 125.2, 125.4, 126.4, 127.3, 127.5, 128.8, 129.2, 129.4, 129.5, 
132.2, 132.4, 139.4, 133.9, 142.0, 143.8, 150.3, 150.7, 156.4; MS: 
m/z = 458.55 (calculated), m/z = 459.1 [M+H]+ (found); elemental 
composition calculated for C31H26N2O2: C, 81.20; H, 5.72; N, 6.11; O, 
6.98; found: C, 81.23; H, 5.79; N, 6.13; O, 6.99. 
4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-4-carbaldehyde (8e) 
Yield 78%; yellow solid; mp 119–121 °C; FT-IR (cm-1): 2251, 2125, 
1661, 1052, 1024, 1005, 821, 758, 624; 1H NMR (400 MHz, DMSO-
d6): δ 3.27 (dd, J1-2 = 17.2 Hz, J1-1 = 4.4 Hz, 1H, C4-H isoxazoline), 
3.39-3.43 (m, 1H, C4-H isoxazoline), 3.78 (dd, J1-2 = 13.2 Hz, J1-1 = 6.0 
Hz, 1H, N-CH), 4.01 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.72-
4.76 (m, 1H, C5-H isoxazoline), 6.73 (d, J = 2.8 Hz, 2H, ArH), 6.97-
7.31 (m, 8H, ArH), 7.67 (t, J = 7.2 Hz, 3H, ArH), 7.79 (dd, J1-2 = 6.8 Hz, 
J1-1 = 1.6 Hz, 2H, ArH), 7.87-7.90 (m, 1H, ArH), 8.00-8.03 (m, 1H, 
ArH), 8.20 (t, J = 1.6 Hz, 1H, ArH), 10.06 ( s, 1H, CHO); 13C NMR (100 
MHz, DMSO-d6): δ 38.2, 54.2, 78.8, 121.4, 124.1, 127.5, 127.6, 
128.3, 128.8, 129.5, 130.3, 132.2, 132.4, 132.9, 133.9, 137.3, 140.4, 
140.5, 150.3, 150.6, 156.4, 193.6; MS: m/z = 456.53 (calculated), 
m/z = 457.0 [M+H]+ (found); elemental composition calculated for 
C31H24N2O2: C, 81.56; H, 5.30; N, 6.14; O, 7.01; found: C, 81.58; H, 
5.37; N, 6.16; O, 7.02. 
5-[3-(4'-Methoxy-biphenyl-4-yl)-4,5-dihydro-isoxazol-5-ylmethyl]-
5H-dibenzo[b,f]azepine (8f) 
Yield 87%;  pale yellow solid; mp 187–189 °C; FT-IR (cm-1): 2926, 
2853,1777, 1551, 1529, 1424, 1369, 1258, 1222, 1172; 1H NMR (400 
MHz, DMSO-d6): δ 3.28 (dd, J1-2 = 16.8 Hz, J1-1 = 6.4 Hz, 1H, C4-H 
isoxazoline), 3.40 (dd, J1-2 = 16.8 Hz, J1-1 = 10.4 Hz, 1H, C4-H 
isoxazoline), 3.75-3.80 (m, 4H, N-CH and OCH3), 4.05 (dd, J1-2 = 13.6 
Hz, J1-1 = 6.0 Hz, 1H, N-CH), 4.72-4.77 (m, 1H, C5-H isoxazoline), 6.77 
(d, J = 1.6 Hz, 2H, ArH), 7.03 (d, J = 8.8 Hz, 4H, ArH), 7.10-7.32 (m, 
6H, ArH), 7.61-7.69 (m, 6H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 
38.2, 54.2, 55.6, 78.5, 114.9, 124.0, 126.7, 127.4, 128.1, 128.2, 
129.5, 131.9, 132.2, 132.5, 133.9, 141.5, 156.5, 159.7; MS: m/z = 
458.55 (calculated), m/z = 459.10 [M+H]+ (found); elemental 
composition calculated for C31H26N2O2: C, 81.20; H, 5.72; N, 6.11; O, 
6.98; found: C, 81.23; H, 5.79; N, 6.13; O, 6.99. 
5-[3-(4'-Trifluoromethoxy-biphenyl-4-yl)-4,5-dihydro-isoxazol-5-
ylmethyl]-5H-dibenzo[b,f]azepine (8g) 
Yield 80%; yellow solid; mp 165–167 °C; FT-IR (cm-1): 2902, 2260, 
2128, 1662, 1075, 1021, 987; 1H NMR (400 MHz, DMSO-d6): δ 3.25 
(dd, J1-2 = 17.2 Hz, J1-1 = 6.8 Hz, 1H, C4-H isoxazoline), 3.37 (dd, J1-2 = 
17.2 Hz, J1-1 = 10.9 Hz, 1H, C4-H isoxazoline), 3.75  (dd, J1-2 = 14.0 Hz, 
J1-1 = 6.4 Hz, 1H, N-CH), 4.01 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 1H, N-
CH), 4.70-4.75 (m, 1H, C5-H isoxazoline), 6.73 (d, J = 2.4 Hz, 2H, 
ArH), 6.96-7.29 (m, 8H, ArH), 7.41 (d, J = 8 Hz, 2H, ArH), 7.62 (d, J = 
8.4 Hz, 2H, ArH), 7.70 (d, J = 8 Hz, 2H, ArH), 7.77 (d, J = 8.8 Hz, 2H, 
ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.2, 54.1, 78.7, 119.2, 
121.3, 121.3, 121.8, 121.9, 124.0, 127.5, 127.6, 129.0, 129.3, 129.4, 
129.5, 132.2, 132.4, 133.9, 138.9, 140.3, 148.5, 150.3, 150.7, 156.4; 
MS: m/z = 512.525 (calculated), m/z = 513.10 [M+H]+ (found); 
elemental composition calculated for C31H23F3N2O2: C, 72.65; H, 
4.52; F, 11.12; N, 5.47; O, 6.24; found: C, 72.67; H, 4.57; N, 5.48; O, 
6.25. 
4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-4-carbonitrile (8h) 
Yield 84%; pale yellow solid; mp 190–193 °C; FT-IR (cm-1): 2971, 
1483, 1457, 1226, 1052, 907; 1H NMR (400 MHz, DMSO-d6): δ 3.29 
(dd, J1-2 = 16.8 Hz, J1-1 = 6.4 Hz, 1H, C4-H isoxazoline), 3.40 (dd,  J1-2 = 
12.0 Hz, J1-1 = 6.8 Hz, 1H, C4-H isoxazoline), 3.78 (dd, J1-2 = 13.2 Hz, 
J1-1 = 6.0 Hz, 1H, N-CH), 4.04 (dd, J1-2 = 14.0 Hz, J1-1 = 6.4 Hz, 1H, N-
CH), 4.73 (m, 1H, C5-H isoxazoline), 6.72 (d, J = 2.8 Hz, 2H, ArH), 
6.99-7.28 (m, 8H, ArH), 7.64-7.76 (m, 2H, ArH), 7.76-7.85 (m, 2H, 
ArH), 7.85-7.91 (m, 4H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.1, 
54.2, 78.9, 110.8, 119.2, 121.3, 124.0, 127.6, 127.8, 127.9, 129.5, 
130.1, 132.2, 132.4, 133.3, 133.9, 139.8, 144.0, 150.3, 150.6, 156.3; 
MS: m/z = 453.53 (calculated), m/z = 454.0 [M+H]+ (found); 
elemental composition calculated for C31H23N3O: C, 82.10; H, 5.11; 
N, 9.27; O, 3.53; Found: C, 82.13; H, 5.16; N, 9.29; O, 3.54. 
[4'-(5-Dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-isoxazol-3-yl)-
biphenyl-4-ylmethyl]-phenyl-amine (8i) 
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Yield 77%; pale brown solid; mp 173–175 °C; FT-IR (cm-1): 3444, 
2251, 1661, 1053, 1005; 1H NMR (400 MHz, DMSO-d6): δ 3.26 (dd, 
J1-2 = 13.6 Hz, J1-1 = 6.8 Hz, 1H, C4-H isoxazoline), 3.36 (dd, J1-2 = 14.8 
Hz, J1-1 = 8.4 Hz, 1H, C4-H isoxazoline), 3.76 (dd, J1-2 = 14.0 Hz, J1-1 = 
6.4 Hz, 1H, N-CH), 4.01 (dd, J1-2 = 14.0 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 
4.30 (d, J = 5.6 Hz, 2H, N-CH2), 4.72 (m, 1H, C5-H isoxazoline), 6.22 (t, 
J = 6.0 Hz, 1H, ArH), 6.47 (t, J = 7.2 Hz, 1H, ArH), 6.58 (dd, J1-2 = 8.8 
Hz, J1-1 = 0.8 Hz, 2H, ArH), 6.73 (d, J = 2.4 Hz, 2H, ArH), 6.99-7.02 (m, 
4H, ArH), 7.06-7.26 (m, 6H, ArH), 7.33-7.40 (m, 2H, ArH), 7.51 (dd, 
J1-1 = 7.6 Hz, J1-2 = 1.6 Hz, 1H, ArH), 7.61 (d, J = 8.8 Hz, 2H, ArH), 
6.65-7.67 (m, 3H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.2, 46.9, 
54.2, 78.6, 112.8, 116.2, 121.3, 124.0, 125.4, 125.9, 126.0, 127.3, 
127.5, 128.8, 129.2, 129.4, 129.5, 132.2, 132.4, 133.9, 139.6, 141.6, 
141.9, 149.0, 150.3, 150.7, 156.4; MS: m/z = 533.66 (calculated), 
m/z = 534.8 [M+H]+ (found); elemental composition calculated for 
C37H31ClN3O: C, 83.27; H, 5.86; N, 7.87; O, 3.00; found: C, 83.29; H, 
5.90; N, 7.88; O, 3.01. 
5-[3-(4-Thiophen-2-yl-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-
5H-dibenzo[b,f]azepine (8j) 
Yield 87%; pale brown solid; mp 173–175 °C; FT-IR (cm-1): 2958. 
1736, 1592, 1483, 1458, 1434, 1360, 1336, 1298, 1246, 1161; 1H 
NMR (400 MHz, DMSO-d6): δ 3.25 (dd, J1-2 = 17.2 Hz, J1-1 = 6.8 Hz, 
1H, C4-H isoxazoline), 3.37 (dd, J1-2 = 17.2 Hz, J1-1 = 10.8 Hz, 1H, C4-H 
isoxazoline), 3.76 (dd, J1-2 = 14.0 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 3.97-
4.02 (m, 1H, N-CH), 4.69-4.73 (m, 1H, C5-H isoxazoline), 6.73 (d, J = 
2.8 Hz, 2H, ArH), 6.98-7.28 (m, 9H, ArH), 7.55-7.56 (m, 4H, ArH), 
7.67 (d, J = 8.4 Hz, 2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.1, 
54.2, 78.7, 121.3, 124.0, 124.9, 125.9, 126.8, 127.6, 128.7, 129.1, 
129.5, 132.2, 132.4, 133.8, 135.4, 142.8, 150.37, 150.70, 156.3; MS: 
m/z = 434.55 (calculated) m/z = 435.2 [M+H]+ (found); elemental 
composition calculated for C28H22N2OS: C, 77.39; H, 5.10; N, 6.45; O, 
3.68; S, 7.38; found: C, 77.41; H, 5.17; N, 6.47; O, 3.69. 
5-[3-(4-Pyridin-4-yl-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-5H-
dibenzo[b,f]azepine (8k) 
Yield 86%; yellow solid; mp 108-110 °C; FT-IR (cm-1): 2269, 2246, 
2177, 1622, 1085, 901; 1H NMR (400 MHz, DMSO-d6): δ 3.25 (dd, J1-2 
= 17.2 Hz, J1-1 = 6.8 Hz, 1H, C4-H isoxazoline), 3.37 (dd, J1-2 = 17.2 Hz, 
J1-1 = 10.9 Hz, 1H, C4-H isoxazoline), 3.75 (dd,  J1-2 = 14.0 Hz, J1-1 = 6.4  
Hz, 1H, N-CH), 4.01 (dd, J1-2 = 13.6 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.71-
4.76 (m, 1H, C5-H isoxazoline), 6.73 (d, J = 2.4 Hz, 2H, ArH), 6.98-
7.27 (m, 8H, ArH), 7.68 (d, J = 8.0 Hz, 2H, ArH), 7.83 (d, J = 8.4 Hz, 
2H, ArH), 8.64 (s, 2H, ArH); 13C NMR (100 MHz, DMSO-d6): δ 38.1, 
54.1, 78.9, 121.3, 124.0, 127.5, 127.6, 129.3, 129.5, 130.6, 132.2, 
132.5, 133.9, 138.7, 146.3, 150.3, 150.7, 156.4; MS: m/z = 429.51 
(calculated), m/z = 430.1 [M+H]+ (found); elemental composition 
calculated for C29H23N3O: C, 81.09; H, 5.40; N, 9.78; O, 3.73; found: 
C, 81.91; H, 5.45; N, 9.79; O, 3.74. 
6-Chloro-5-[4-(5-dibenzo[b,f]azepin-5-ylmethyl-4,5-dihydro-
isoxazol-3-yl)-phenyl]-1,3-dihydro-indol-2-one (8l) 
Yield 70%; yellow solid; mp 160–162 °C; FT-IR (cm-1): 3441, 2988, 
2251, 2125, 1661, 1052, 1024, 1005; 1H NMR (400 MHz, DMSO-d6): 
δ 3.29 (dd, J1-2 = 16.8 Hz, J1-1 = 6.4 Hz, 1H, C4-H isoxazoline); 3.40 
(dd, J1-2 = 12.0 Hz, J1-1 = 6.8 Hz, 1H, C4-H isoxazoline), 3.45 (s, 2H, 
CH2), 3.78 (dd, J1-2 = 13.2 Hz, J1-1 = 6.0 Hz, 1H, N-CH), 4.04 (dd, J1-2 = 
14.0 Hz, J1-1 = 6.4 Hz, 1H, N-CH), 4.74-4.78 (m, 4H, C5-H isoxazoline), 
6.77 (d, J = 1.6 Hz, 2H, ArH), 6.94 (s, 1H, ArH), 7.02-7.32 (m, 9H, 
ArH), 7.41-7.44 (m, 2H, ArH), 7.62-7.64 (m, 2H, ArH), 10.58 (s, 1H, 
NH); 13C NMR (100 MHz, DMSO-d6): δ 35.82, 38.25, 54.20, 78.6, 
110.4, 121.3, 124.0, 126.0, 126.7, 127.3, 127.4, 128.7, 129.5, 130.1, 
130.2, 132.1, 132.2, 132.4, 133.9, 140.9, 145.0, 150.3, 150.7, 156.5, 
176.7; MS: m/z = 518.00 (calculated), m/z = 520.2 [M+2H]+ (found); 
elemental composition calculated for C32H24ClN3O2: C, 74.20; H, 
4.67; Cl, 6.84; N, 8.11; O, 6.18; found: C, 74.23; H, 4.72; N, 8.13; O, 
6.19. 
 
 
Assessment of antimalarial activity  
P. falciparum parasites were cultured according to the method of 
Trager and Jensen.40 Briefly, 3D7, D6, W2 and 7G8 P. falciparum 
strains were cultured in RPMI 1640 medium (Gibco) supplemented 
with 25 mM HEPES, 29 mM sodium bicarbonate, 0.005% 
hypoxanthine, p-aminobenzoic acid (2 mg/liter), gentamycin sulfate 
(50 mg/liter) and 5% AlbuMAX II (Invitrogen) using fresh O-positive 
human red blood cells at 2% hematocrit. The cultures were 
maintained at 37 °C under 5% O2, 5% CO2, and 90% N2. The 
antimalarial activity of isoxazoline compounds were determined by 
a fluorometric method using SYBR Green I.41,42 Briefly, stock 
solutions of isoxazoline were prepared in DMSO (10 mM) and were 
serially diluted with complete culture medium to give 
concentrations ranging from 0.2 to 200 µM and the final 
concentration of DMSO was less than 0.1%. 100 µL of each testing 
solution was mixed with 100 µL of 0.2% parasitized red blood cells 
in the ring stage at 2% hematocrit in complete medium and 
dispensed into 96-well plates. Untreated- and DMSO (0.1%) vehicle-
treated parasites were used as controls. The plates were incubated 
at 37 °C for 72 h and the experiment was performed in triplicate. To 
each well, 100 µL of lysis buffer (20 mM Tris-HCl, pH 7.5, 5 mM 
EDTA, 0.008% saponin, 0.08% Triton X-100) containing 0.2 µL/mL of 
SYBR Green I (Life Technology) was added. The plates were 
wrapped with aluminium foil and incubated in the dark at room 
temperature for 1 h. The fluorescence intensity was measured using 
multi-well plate fluorescence reader at an excitation and emission 
wavelengths of 485 and 535 nm, respectively. The values were 
expressed as relative fluorescence units. The IC50 values (the 
effective concentrations that inhibit parasite growth by 50%) of 
three independent experiments were plotted using nonlinear 
regression (Sigmoidal dose response) equation (GraphPad Prism 
version 4.01, GraphPad Software, La Jolla, CA). 
 
Cytotoxicity assay 
The toxicity of 3,5-disubstituted isoxazoline derivaives against 
human cells was assessed by the MTS assay43,44 using human 
embryonic kidney cells (HEK 293 cell line) and human 
adenocarcinoma epithelial cells (A549 cell line). Briefly, 5×103 
cells/well in 100 µL of  DMEM medium supplemented with 10% 
bovine fetal serum were plated in 96-well plates. After 24 h, the 
stock solutions of 3,5-disubstituted isoxazoline in DMSO that were 
serially diluted to obtain concentrations ranging from 0.5 µM to 200 
µM in 100 µl complete medium was added to each well and 
incubated at 37 °C for 72 h. The cells treated with DMSO (1%) alone 
were used as vehicle controls. To each well added 20 µl of 
MTS/PMS reagent (Promega, Madison, WI), incubated for 3 h at 37 
°C and the absorbance measured at 490 nm. The assay was 
performed in triplicate and the values from three independent 
experiments were used to calculate the IC50 values (GraphPad Prism 
version 4.01). 
 
Molecular modelling methods 
The software used for all computational calculations is Schrödinger 
Software Suite 2015-2 with hardware 2x Intel Xeon 1.9 GHz E5-
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2420/ 6C/15MB Cache RAM 6 x 4Gb DDR-3 1333MHz ECC RDIMM 
4x 500 Gb Graphics Card NvidiaQuadro 600 machine. 
The docking studies of 3,5-disubstituted isoxazoline tethered 
dibenzazepine derivatives with PfA-M1 were performed by using 
Schrödinger Glide.45 The structures were drawn using 2D sketcher 
of Schrödinger maestro 10.2. The ligands were optimised for the 
docking using LigPrep46,47 where the structures were converted to 
3D and energy optimised using OPLS2005. Ionisation states were 
generated for all molecules at pH range 7.0 ± 2 using Epik module, 
in LigPrep with all other default options. 3D structure of inhibitor 
bound PfA-M1 was retrieved in form from protein data bank35 (PDB 
ID: 4X2U). The downloaded protein structure was refined using 
Protein preparation wizard where in missing hydrogen atoms, 
amino acid side chains and missing residues were added and bond 
order were set. The unnecessary hetero atoms and water molecules 
were deleted except the Zn+2 and co-crystallised inhibitor. The 
structure was optimized to create H-bond network and finally 
minimized to remove any steric clashes using OPLS2015 force 
field.48 The fully optimized protein structure was used for the 
receptor grid generation using Glide software.49 The grid was 
generated by choosing the centroid of bound ligand as the centroid 
of the grid. The prepared ligands were docked to protein grid using 
extra precession (XP) mode. The protein-ligand complex was further 
analysed and visualized using Maestro. 
 
Molecular dynamics simulation analysis 
The molecule (6k) that exhibited excellent antimalarial activity and 
low toxicity to human cells was assessed by molecular dynamics 
analysis to determine the binding stability and the binding pattern. 
The protein complex docked with the inhibitor was submitted for 
10 ns simulation. The molecular dynamics simulation was run using 
Desmond.50 The orthorhombic simulation box was prepared using 
the system builder panel of Desmond with TIP3P explicit water 
model so that the minimum distance between the protein surface 
and the solvent surface is 10 Å. The counter ions were added to 
neutralise the system and 0.15 M NaCl was used to provide the iso-
osmotic salt environment. The system was minimized with 2000 
iterations and with convergence criteria of 1 kcal/mol/Å. The 
minimised system was subjected to the 10 ns molecular dynamic 
simulation using NPT ensemble at temperature of 300K and 
atmospheric pressure (1.013 bars) with the default setting of 
relaxation before simulation. The Nose-Hoover Chain thermostat 
and Matrtyna-Tobias-Klein barostate was used to maintain the 
temperature and pressure, respectively. The time step of 2 fs was 
considered during the simulation and every 10 ps, the energy and 
structure was recorded and saved in the trajectory. From the 
trajectory generated, the simulation interaction diagram was 
generated to analyse the results. 
 
Conclusions 
In summary, we have synthesized dibenzazepine tethered 3,5-
disubstituted isoxazolines, and evaluated their antimalarial 
activity against P. falciparum drug-sensitive 3D7 strains and 
toxicity to human lung cancer A549 and kidney HEK 293 cells. 
Several compounds that showed low cytotoxic activity 
effectively inhibited the growth of parasite. Compounds (6j, 
6k, 8c, 8k and 8l) that showed excellent antimalarial activity in 
initial screening were further assessed using an additional 
chloroquine-sensitive parasite strain (D6) and two 
chloroquine-resistant parasite strains (W2 and 7G8). Molecular 
docking studies revealed the mode of the dibenzazepine 
derivatives binding to PfA-M1. The molecular dynamics 
simulation confirmed the stability of the binding mode of the 
ligand 6k predicted by docking studies. The co-ordination bond 
formed between the isoxazoline moiety of the ligand and the 
enzyme-bound Zn+2 ion, π−π interaction between 
dibenzazepine and His496, and π−cation interactions between 
piperidine moiety and Tyr575, and hydrophobic interactions 
with residues Val493, Val523, Tyr580, Tyr575, Val459, Met462, 
Met1034, Ala320 stabilized the dibenzazepine binding to PfA-
M1. Our experimental and theoretical finding data show that, 
several compounds possess excellent antimalarial activity with 
minimal or no cytotoxicity. Thus, overall our results suggest 
that the dibenzazepine tethered 3,5-disubstituted isoxazolines 
are promising candidates for the development of antimalarial 
drugs. 
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